Detail

Basic Information

LncRNA/CircRNA Name	circBMPR2
Synonyms
Region
Ensemble
Refseq

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis	apoptosis	Drug	Tamoxifen
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	breast cancer
ICD-0-3	C50
Methods	qRT-PCR , luciferase reporter assay , RIP , Microarray , actinomycin D and RNase R treatment , MTT Assay , colony formation assay , cell-cycle assay , cell Apoptosis Analysis , wound-healing assay , transwell migration and invasion assays , subcellular fractionation location
Sample	breast cancer tissues and paired adjacent non-tumorous tissues ,cell lines(MCF-7, MDA-MB-231, MDA-MB-468, and HEK293T cells ,T47D, SKBR3, and ZR-75-1 cells)
Expression Pattern	down-regulated
Function Description	In this study, we identified a novel circRNA (named circBMPR2) whose expression was lower in breast cancer tissues with metastasis. Moreover, circBMPR2 expression was negatively associated with the motility of breast cancer cells and significantly downregulated in human breast cancer tissues. Functionally, circBMPR2 knockdown effectively enhanced cell proliferation, migration, and invasion. Moreover, circBMPR2 knockdown promoted tamoxifen resistance of breast cancer cells through inhibiting tamoxifen-induced apoptosis, whereas circBMPR2 overexpression led to decreased tamoxifen resistance. Mechanistically, circBMPR2 could abundantly sponge miR-553 and that miR-553 overexpression could attenuate the inhibitory effects caused by circBMPR2 overexpression. We also found that ubiquitin-specific protease 4 (USP4) was a direct target of miR-553, which functions as a tumor suppressor in breast cancer.
Pubmed ID	31302495
Year	2019
Title	Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer

External Links

Links for circBMPR2	GenBank HGNC NONCODE
Links for breast cancer	OMIM COSMIC